Prenetics Global Limited (PRE)
| Previous Close | 1.5000 |
| Open | 1.5000 |
| Bid | 1.4500 x 1100 |
| Ask | 1.4800 x 1100 |
| Day's Range | 1.4589 - 1.5200 |
| 52 Week Range | 1.2400 - 8.7500 |
| Volume | |
| Avg. Volume | 889,486 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.55 |
- GlobeNewswire
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the company realizes the full potential of its broad genetics and digital testing platform and as a commitment to the EMEA market. To be effective immediately, Dr. Bayju Thakar is appointed as CEO and shall join the board of directors for Prenetics EMEA Limited (“Prenetics EMEA”), a wholly owned subsidi
- ACCESSWIRE
Sidoti's January Micro-Cap Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.
- GlobeNewswire
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology marketFDA market authorization advances personalized cancer care in AsiaClearance sets the stage for continued R&D investment into early detection / liquid biopsy LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which
